Search Result

Results for "

CDK7+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (10) c-Myc (3) Caspase (1) CDK (39) DNA/RNA Synthesis (3) Early 2 Factor (E2F) (2) JAK (1) Reference Standards (1) Ser/Thr Kinase (1) Topoisomerase (2)
By Research Areas:	Cancer (38)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138293

SY-5609 5+ Cited Publications CDK7-IN-3	CDK Apoptosis	Cancer
SY-5609 (CDK7-IN-3) is an orally active, highly selective, noncovalent *CDK7* inhibitor with a K_D of 0.065 nM. SY-5609 shows poor inhibition on CDK2 (K_i=2600 nM), CDK9 (K_i=960 nM), CDK12 (K_i=870 nM). SY-5609 induces apoptosis in tumor cells and has antitumor activity .

HY-103712A

Samuraciclib hydrochloride 10+ Cited Publications CT7001 hydrochloride; ICEC0942 hydrochloride	CDK Apoptosis	Cancer
Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active *CDK7* inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 µM. Samuraciclib hydrochloride has anti-tumor effects .

HY-80013

THZ1 Maximum Cited Publications 93 Publications Verification	CDK	Cancer
THZ1 is a selective and potent covalent *CDK7* inhibitor with an IC₅₀ of 3.2 nM. THZ1 also inhibits the closely related kinases CDK12 and CDK13 and downregulates MYC expression .

HY-101257

YKL-5-124 15+ Cited Publications	CDK	Cancer
YKL-5-124 is a potent, selective, irreversible and covalent *CDK7* inhibitor with IC₅₀s of 53.5 nM and 9.7 nM for *CDK7* and *CDK7/Mat1/CycH, respectively. YKL-5-124 is >100-fold greater selective for CDK7* than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .

HY-153278

Q901 CDK7-IN-21	CDK DNA/RNA Synthesis c-Myc Early 2 Factor (E2F) Topoisomerase	Cancer
Q901 (CDK7-IN-21) is a selective and potent *CDK7* inhibitor with an IC₅₀ of 10 nM. Q901 disrupts MYC and E2FTOP1-DPCs and sensitizes tumor to TOP1 inhibitors by suppressing RNAPII transition from initiation to elongation. Q901 can inhibit tumor growth and significantly enhances tumor growth inhibition combined with TOP1 inhibitors. Q901 can be used for the research of cancer, such as colon cancer and lung cancer .

HY-103712

Samuraciclib 10+ Cited Publications CT7001; ICEC0942	CDK Apoptosis	Cancer
Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active *CDK7* inhibitor, with an IC₅₀ of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 μM. Samuraciclib has anti-tumor effects .

HY-12280

THZ2 5 Publications Verification	CDK	Cancer
THZ2 is a potent and selective *CDK7* inhibitor with an IC₅₀ of 13.9 nM.

HY-13266A

BS-181 hydrochloride 5+ Cited Publications	CDK	Cancer
BS-181 hydrochloride is a highly selective *CDK7* inhibitor with IC₅₀ of 21 nM, and > 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.

HY-80013A

THZ1 Hydrochloride Maximum Cited Publications 93 Publications Verification	CDK	Cancer
THZ1 Hydrochloride is a selective and potent covalent *CDK7* inhibitor with an IC₅₀ of 3.2 nM. THZ1 Hydrochloride also inhibits the closely related kinases CDK12 and CDK13 and downregulates MYC expression .

HY-128587

Mevociclib 5+ Cited Publications SY-1365	CDK	Cancer
Mevociclib (SY-1365) is a potent and first-in-class selective *CDK7* inhibitor, with a K_i of 17.4 nM. Mevociclib exhibits anti-proliferative and apoptotic effects in solid tumor cell lines. Mevociclib possesses anti-tumor activity in hematological and multiple aggressive solid tumors .

HY-128867

bio-THZ1 1 Publications Verification	CDK	Cancer
bio-THZ1 is a biotinylated version of THZ1 and binds irreversibly to CDK7. THZ1 is a selective and potent covalent *CDK7* inhibitor with an IC₅₀ of 3.2 nM .

HY-103712C

Samuraciclib hydrochloride hydrate 10+ Cited Publications CT7001 hydrochloride hydrate; ICEC0942 hydrochloride hydrate	CDK Apoptosis	Cancer
Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active *CDK7* inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects .

HY-103712B

Samuraciclib hydrochloride dihydrate 10+ Cited Publications CT7001 hydrochloride dihydrate; ICEC0942 hydrochloride dihydrate	CDK Apoptosis	Cancer
Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active *CDK7* inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects .

HY-101257B

YKL-5-124 TFA 15+ Cited Publications	CDK	Cancer
YKL-5-124 TFA is a potent, selective, irreversible and covalent *CDK7* inhibitor with IC₅₀s of 53.5 nM and 9.7 nM for *CDK7* and *CDK7/Mat1/CycH, respectively. YKL-5-124 TFA is >100-fold greater selective for CDK7* than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 TFA induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .

HY-147600

CDK7-IN-15	CDK	Cancer
CDK7-IN-15 (Compound 8) is a selective *CDK7* inhibitor with an IC₅₀ greater than 10 nM and less than or equal to 100 nM. CDK7-IN-15 is applicable to the research of cancers associated with transcriptional dysregulation .

HY-18969

LDC3140	CDK	Cancer
LDC3140 is a selective CDK7 inhibitor (IC₅₀<5 nM). By inhibiting the activity of CDK7, LDC3140 affects the regulation of the cell cycle, leading to cell cycle arrest and thus inhibiting the proliferation of tumor cells. LDC3140 can be used in the research of cancer treatment .

HY-163856

CDK7-IN-30	Apoptosis DNA/RNA Synthesis CDK	Cancer
CDK7-IN-30 (Compound 22) is a *CDK7* inhibitor (IC₅₀ = 7.21 nM) that effectively inhibits the phosphorylation of RNA Polymerase II and CDK2. CDK7-IN-30 CDK7-IN-30 can induce cell apoptosis and has anti-cancer activity and can be used in cancer research .

HY-13266

BS-181	CDK Apoptosis	Cancer
BS-181 is a potent and selective *CDK7* inhibitor (IC₅₀=21 nM) than Seliciclib (HY-30237). BS-181 is also against CDK2, CDK5 and CDK9 with IC₅₀ values of 880, 3000 and 4200 nM, respectively (fails to block CDK1, 4 and 6). BS-181 inhibits a panel of cancer cells growth (IC₅₀=11.5 μM-37.3 μM) and induces cell apoptosis. BS-181 has the potential for the research of cancer therapy .

HY-145655

CDK7-IN-11	CDK	Cancer
CDK7-IN-11 is an orally active *CDK7* inhibitor. CDK7-IN-11 exhibits high CDK7 inhibitory activity with IC₅₀ value of 4.2 nM. CDK7-IN-11 can be effectively used for the research of diseases associated with CDK7 .

HY-153278A

Q901 TFA CDK7-IN-21 TFA	CDK DNA/RNA Synthesis c-Myc Early 2 Factor (E2F) Topoisomerase	Cancer
Q901 (CDK7-IN-21) TFA is a selective and potent *CDK7* inhibitor with an IC₅₀ of 10 nM. Q901 TFA disrupts MYC and E2FTOP1-DPCs and sensitizes tumor to TOP1 inhibitors by suppressing RNAPII transition from initiation to elongation. Q901 TFA can inhibit tumor growth and significantly enhances tumor growth inhibition combined with TOP1 inhibitors. Q901 TFA can be used for the research of cancer, such as colon cancer and lung cancer .

HY-153950

CDK7-IN-22	CDK	Cancer
CDK7-IN-22 (compound 101) is an *CDK7* inhibitor with antitumor activity. CDK7-IN-22 shows selectivity on CDK7 .

HY-139011

IV-361 1 Publications Verification	CDK	Cancer
IV-361 is an orally active and selective *CDK7* inhibitor (K_i≤50 nM). IV-361 has anti-cancer activity (US20190256531A1) .

HY-139986

CDK7-IN-5	CDK	Cancer
CDK7-IN-5 is a *CDK7* inhibitor with an IC₅₀ value <100 nM. CDK7-IN-5 has anticancer effects. (WO2015154022A1 (Compound 104)) .

HY-101257A

CDK7-IN-1	CDK	Cancer
CDK7-IN-1, an analog of YKL-5-124, is a cyclin-dependent kinase 7 (cdk7) inhibitor, with an IC₅₀ of less than 100 nM, extracted from patent WO 2016105528 A2, Compound 215 .

HY-145389

SZ-015268	CDK	Cancer
SZ-015268 is a *CDK7* inhibitor with an IC₅₀ of 23.56 nM. SZ-015268 has extremely significant anti-tumor advantages. SZ-015268 inhibits HCC70, OVCAR-3, HCT116 and HCC1806 cells proliferation with IC₅₀s of 33, 80.56, 12.53, and 61.55 nM, respectively .

HY-157210

CDK7-IN-26	CDK	Cancer
CDK7-IN-26 (compound 36) is an orally active *CDK7* inhibitor (IC₅₀: 7.4 nM). CDK7-IN-26 potently inhibits the growth of triple-negative breast cancer (TNBC) cell line-derived xenograft (CDX) tumors in vivo and inhibits MDA-MB-453 cells in vitro with an IC₅₀ of 0.15 μM .

HY-145394

CDK7-IN-6	CDK	Cancer
CDK7-IN-6 is a potent and selective cyclin-dependent kinase (CDK7) inhibitor (IC₅₀≤100 nM), extracted from patent WO2019197549 A1, compound 210. CDK7-IN-6 is > 200-fold selective for CDK7 over CDK1, CDK2, and CDK5. CDK7-IN-6 can be used for the research of cancer .

HY-110368

BS-181 dihydrochloride	CDK	Cancer
BS-181 dihydrochloride is a potent and selective *CDK7* inhibitor (IC₅₀=21 nM) than Seliciclib (HY-30237). BS-181 is also against CDK2, CDK5 and CDK9 with IC₅₀ values of 880 nM, 3000 nM and 4200 nM, respectively (fails to block CDK1, 4 and 6). BS-181 dihydrochloride inhibits a panel of cancer cells growth (IC₅₀=11.5 μM-37.3 μM) and induces cell apoptosis. BS-181 dihydrochloride has the potential for the research of cancer therapy .

HY-170425

CDK7-IN-32	CDK	Cancer
CDK7-IN-32 (compound10) is a *CDK7* inhibitor .

HY-156705

CDK7-IN-25	CDK	Cancer
CDK7-IN-25 (CY-16-1) is a *CDK-7* inhibitor (IC₅₀<1nM) that can be used in cancer research .

HY-136711

CDK7-IN-2 hydrochloride hydrate	CDK	Cancer
CDK7-IN-2 hydrochloride hydrate (Example 6) is a potent and selective *CDK7* inhibitor. CDK7-IN-2 has potent anti-cancer activity .

HY-143586

CDK7-IN-8	CDK	Cancer
CDK7-IN-8 is a potent *CDK7* inhibitor with IC₅₀ of 54.29 nM. CDK7-IN-8 has inhibitory effect on certain cancer cells and in vivo tumor models .

HY-147601

CDK7-IN-16	CDK	Cancer
CDK7-IN-16 (compound 9) is a potent *CDK 7* inhibitor with an IC₅₀ range of 1 ~ 10 nM. CDK7-IN-16 can be used for researching anticancer, especially the cancer with transcriptional dysregulation .

HY-169344

CDK7-IN-31	CDK	Cancer
CDK7-IN-31 (compound 13) is a potent and orally active cyclin-dependent kinase 7 (CDK7) inhibitor with a K_d value of 0.18 nM. CDK7-IN-31 shows anticancer activity .

HY-145424

CDK7-IN-10	CDK	Others
CDK7-IN-10 is a *CDK7* inhibitor with an IC₅₀ of less than 100 nM, extracted from patent WO2021016388A1, compound I-1. CDK7-IN-10 is useful in inhibiting the activity of a kinase. CDK7-IN-10 has the potential of inhibiting cell growth and inducing cell apoptosis .

HY-172194A

(S)-JNJ-3738	CDK	Cancer
(S)-JNJ-3738 is a *CDK7* inhibitor. (S)-JNJ-3738 regulates kinase activity and exerts weak inhibitory effects on the activity of mutant *CDK7*. (S)-JNJ-3738 is applicable for cancer research .

HY-103712AR

Samuraciclib hydrochloride (Standard) CT7001 hydrochloride (Standard); ICEC0942 hydrochloride (Standard)	Reference Standards CDK Apoptosis	Cancer
Samuraciclib hydrochloride (Standard) is the analytical standard of Samuraciclib hydrochloride (HY-103712A). This product is intended for research and analytical applications. Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib hydrochloride has anti-tumor effects .

HY-180355

SY-5102	CDK Ser/Thr Kinase c-Myc Apoptosis	Cancer
SY-5102 is a potent, selective and orally active cyclin-dependent kinase (CDK7) inhibitor with a K_d of 0.03 nM. SY-5102 shows anti-proliferative activity against HCC70 cells with an EC₅₀ of 9 nM. SY-5102 can inhibit CDK7-mediated CAK function (downregulate CDK2 Thr160 phosphorylation) and TFIIH transcription function (downregulate RNA polymerase II Ser5 phosphorylation). SY-5102 can induce G2/M cell cycle arrest, downregulate the expression of the oncogene c-Myc, and ultimately trigger cancer cell apoptosis. SY-5102 can be used for the research of triple-negative breast cancer (TNBC) .

HY-181528

JAK1/CDK7-IN-1	JAK CDK Apoptosis Caspase	Cancer
JAK1/CDK7-IN-1 is a *JAK1/CDK7** inhibitor. JAK1/CDK7-IN-1* forms a stable and tightly bound complex with JAK1. JAK1/CDK7-IN-1 disrupts the cell cycle, induces G₂/M phase arrest, and increases the proportion of pre-G₁ phase cells. JAK1/CDK7-IN-1 induces cellular apoptosis (apoptosis) and necrosis. JAK1/CDK7-IN-1 is applicable to research related to breast cancer and prostate cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CDK7+inhibitor

Inhibitors & Agonists